Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

127 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Residual disease detected by multidimensional flow cytometry shows prognostic significance in childhood acute myeloid leukemia with intermediate cytogenetics and negative FLT3-ITD: a report from the Tokyo Children's Cancer Study Group.
Keino D, Kinoshita A, Tomizawa D, Takahashi H, Ida K, Kurosawa H, Koike K, Ota S, Iwasaki N, Fujimura J, Yuza Y, Kiyotani C, Yamamoto S, Osumi T, Ueda T, Mochizuki S, Isoyama K, Hanada R, Tawa A, Manabe A, Toguchi Y, Ohara A. Keino D, et al. Among authors: tawa a. Int J Hematol. 2016 Apr;103(4):416-22. doi: 10.1007/s12185-016-1937-y. Epub 2016 Jan 18. Int J Hematol. 2016. PMID: 26781613 Clinical Trial.
Intensification of chemotherapy using block therapies as consolidation and reinduction therapies for acute lymphoblastic leukemia during childhood.
Hara J, Park YD, Yoshioka A, Yumura-Yagi K, Koudera U, Hosoi G, Sako M, Kosaka Y, Sano K, Misu H, Mabuchi O, Aoyagi N, Yamamoto M, Tawa A, Miyata H, Tanaka H, Kikkawa M, Shimodera M, Kawa-Ha K; Osaka Childhood Leukemia Study Group. Hara J, et al. Among authors: tawa a. Int J Hematol. 2001 Aug;74(2):165-72. doi: 10.1007/BF02982000. Int J Hematol. 2001. PMID: 11594517
Outcome after relapse in childhood acute lymphoblastic leukemia.
Yumura-Yagi K, Hara J, Horibe K, Tawa A, Komada Y, Oda M, Nishimura S, Yoshida M, Kudo T, Ueda K; Japan Association of Childhood Leukemia Study. Yumura-Yagi K, et al. Among authors: tawa a. Int J Hematol. 2002 Jul;76(1):61-8. doi: 10.1007/BF02982720. Int J Hematol. 2002. PMID: 12138898
KIT mutations, and not FLT3 internal tandem duplication, are strongly associated with a poor prognosis in pediatric acute myeloid leukemia with t(8;21): a study of the Japanese Childhood AML Cooperative Study Group.
Shimada A, Taki T, Tabuchi K, Tawa A, Horibe K, Tsuchida M, Hanada R, Tsukimoto I, Hayashi Y. Shimada A, et al. Among authors: tawa a. Blood. 2006 Mar 1;107(5):1806-9. doi: 10.1182/blood-2005-08-3408. Epub 2005 Nov 15. Blood. 2006. PMID: 16291592 Free article.
Prospective study of a pirarubicin, intermediate-dose cytarabine, and etoposide regimen in children with Down syndrome and acute myeloid leukemia: the Japanese Childhood AML Cooperative Study Group.
Kudo K, Kojima S, Tabuchi K, Yabe H, Tawa A, Imaizumi M, Hanada R, Hamamoto K, Kobayashi R, Morimoto A, Nakayama H, Tsuchida M, Horibe K, Kigasawa H, Tsukimoto I; Japanese Childhood AML Cooperative Study Group. Kudo K, et al. Among authors: tawa a. J Clin Oncol. 2007 Dec 1;25(34):5442-7. doi: 10.1200/JCO.2007.12.3687. J Clin Oncol. 2007. PMID: 18048827 Clinical Trial.
127 results